

1 August 2018



## Market data

EPIC/TKR	APH
Price (p)	93.2
12m High (p)	102.5
12m Low (p)	48.8
Shares (m)	514.2
Mkt Cap (£m)	479.2
EV (£m)	567.5
Free Float*	89%
Market	AIM

\*As defined by AIM Rule 26

## Description

APH acquires, markets and distributes medical and healthcare brands in the UK, Europe, and the US (direct sales) and in the RoW (via a distributor network), through a buy-and-build strategy, generating relatively predictable and strong cashflows.

## Company information

CEO Peter Butterfield  
CFO Andrew Franklin  
Chairman David Cook  
+44 1249 466 966  
[www.alliancepharmaceuticals.com](http://www.alliancepharmaceuticals.com)

## Key shareholders

Directors	11.1%
Fidelity	8.9%
MVM Life Sciences	7.9%
Slater Invests.	6.6%
Blackrock	5.0%
GVQ	3.9%
Artemis	3.6%

Diary

19 Sep 1H'18 results

Analysts

Martin Hall            020 7194 7632  
[mh@hardmanandco.com](mailto:mh@hardmanandco.com)  
Dorothea Hill        020 7194 7626  
[dmh@hardmanandco.com](mailto:dmh@hardmanandco.com)  
Grégoire Pavé       020 7194 7628  
[gp@hardmanandco.com](mailto:gp@hardmanandco.com)

ALLIANCE PHARMA

## 2018: a year of international progress

Alliance Pharma (APH) is continuing with its buy-and-build strategy, having evolved through 35 acquisitions over a period of 20 years into a profitable, cash-generative, specialty pharma business. The company has a mix of international growth brands – Kelo-cote, MacuShield, Vamousse – and a bedrock of solid, local, low-growth products. A fourth international growth brand in the portfolio, Nizoral, was acquired from J&J on 21 June 2018 in the APAC region. The cash consideration of £60m was funded by a Placing and an increased debt facility. Adding also to growth prospects, Diclectin (now registered as Xonvea®) was approved in the UK in July.

- ▶ **Strategy:** Since inauguration, APH has adopted a buy-and-build model, with 35 deals over 20 years assembling a portfolio of more than 90 products and establishing a strong track record. It is accelerating growth through investing in multi-market brands, with infrastructure supported by its bedrock products.
  - ▶ **Trading update:** Underlying sales performance for 1H'18 was slightly better than forecast, at 4%, boosted by acquisitions (+8%). Kelo-Cote was exceptional, with CER growth of 88% (est) to £10.9m (£6.2m) offsetting a softer performance from the bedrock portfolio. Net debt at 30 June was also better, at -£86.3m.
  - ▶ **Nizoral:** APH acquired the Nizoral brand (medicated anti-dandruff shampoos) from J&J in the APAC region for a cash consideration of £60.0m, increasing sales in this important region 2.6x and adding well-established multi-national distribution partners and new territories (India and Japan).
  - ▶ **Xonvea (Diclectin):** Adding to the positivity, APH and its partner, Duchesney Inc, received approval for Xonvea (nausea and vomiting of pregnancy) in the UK after a year of dialogue with the MHRA. Launch will take place in autumn 2018. Plans are underway to submit for EMA approval in APH's nine European territories.
  - ▶ **Investment summary:** Recent acquisitions look set to boost APH into generating underlying CAGR of 17% in sales and 10% in EPS over the next three years. On the back of this strong performance, the company is expected to continue with its progressive dividend policy. The shares are trading on a 2018E P/E of 20.1x, falling to 17.6x in 2019E, and carry a prospective dividend yield of 1.6%.

## Financial summary and valuation

<b>Year-end Dec (£m)</b>	<b>2015</b>	<b>2016</b>	<b>2017</b>	<b>2018E</b>	<b>2019E</b>	<b>2020E</b>
Reported sales	48.3	97.5	101.3	119.7	134.0	144.0
EBITDA (underlying)	13.6	26.7	28.2	33.7	39.5	42.0
Reported pre-tax profit	15.2	22.2	*28.4	**28.9	32.7	35.9
Underlying EPS (p)	4.0	4.0	4.2	4.6	5.3	5.8
Reported EPS (p)	4.7	3.9	6.1	4.7	5.0	5.5
DPS (p)	1.1	1.2	1.3	1.5	1.6	1.8
Net (debt)/cash	-71.5	-76.1	-72.3	-87.7	-71.9	-54.7
Net debt/EBITDA (x)	5.3	2.8	2.6	2.6	1.8	1.3
P/E (x)	23.5	23.4	22.0	20.1	17.6	16.1
EV/sales (x)	11.7	5.8	5.6	4.7	4.2	3.9
EV/EBITDA (x)	41.7	21.2	20.1	16.8	14.4	13.5
Dividend yield (%)	1.2	1.3	1.4	1.6	1.7	1.9

\*Includes £5m Sinclair settlement less costs; \*\*Includes £1.5m profit on disposal of Unigreg JV.

settlement less costs; \*\*Includes £1.5m profit on disposal Unigreg JV  
Underlying figures exclude exceptional items and share-based costs

**Source:** Hardman & Co Life Sciences Research



### Reported sales and EBITDA margin




- ▶ The first full year of Nizoral sales in APAC contribute to strong group sales (statutory basis) in 2019E
- ▶ We forecast Xonvea sales of £1.8m from 2019, with rapid growth from 2020 following further EU launches
- ▶ Nizoral sales increase group EBITDA margins in 2018E and 2019E, balancing out costs of launching Xonvea in the UK
- ▶ The end of the TSA period (ca.2020) will result in an 'apparent' drop in the reported EBITDA margin because of the statutory accounting methodology for Nizoral

### Free cashflow and ROIC



- ▶ APH is strongly cash-generative, with forecasts in the range £25m-£30m per annum with a full-year Nizoral contribution
- ▶ Underpinned by the established international star brands and the sustainable bedrock of established products
- ▶ The drop in 2018E FCF results from movement in working capital due, in part, to inventory purchases in connection with recent acquisitions
- ▶ Operating cashflow conversion is typically ca.90% of EBIT; free cashflow definition includes exceptional items

### Net debt and Net debt/EBITDA



- ▶ Net debt will increase in 2018 due to the increased debt facility undertaken to part-fund the Nizoral acquisition
- ▶ At the point of closing the deal with J&J, management indicated that leverage would be 2.5x, which is expected to fall in subsequent years
- ▶ Financial covenants for the life of the credit facility remain at 3.0x to cover potential acquisition spikes

### DPS and dividend cover



- ▶ Progressive dividend policy since payments commenced in 2009
- ▶ We forecast the full-year dividend to rise to 1.46p for 2018
- ▶ There is scope to increase the dividend

Source: Company data; Hardman & Co Life Sciences Research

# 1H'18 trading update

## Key features

- ▶ **Sales:** In 1H'18, reported sales growth of 10% to £54.5m (£49.4m restated for adoption of IFRS 15) was slightly ahead of expectations. The composition of this growth is calculated to be 4.3% organic, 7.8% acquisitions and -1.8% currency.
- ▶ **Kelo-cote:** The star performer was the international brand Kelo-Cote, which saw sales grow 88% to £10.9m (£6.2m). In 2016, this scar treatment became APH's first product to have sales of £10m, a level that it is now achieving in half a year.
- ▶ **MacuShield:** Underlying sales of MacuShield grew 22% to £3.4m (£3.0m restated). This represents another half year of consistent growth, but was slightly below expectations.
- ▶ **Acquisitions:** Both of the products acquired in December 2017 have performed in line with forecasts. Vamousse (head lice) sales were £2.7m (vs. £2.6m forecast) and Ametop sales were estimated at £1.0m (vs. £1.0m forecast).
- ▶ **Adoption of IFRS 15:** 'Revenue from Contracts with Customers' has resulted in a restatement of 1H'17 numbers, lower by £0.9m, which is estimated to be ca.£2.0m for the full-year 2017, and to affect mostly UK-centric products. It is offset by an equivalent figure that has also been taken off the cost of goods sold.
- ▶ **Impact of currency:** APH has a natural currency hedge with overseas sales largely offset by overseas costs. However, in 1H'18, although sales were reduced by £0.9m due to forex, the effect on costs will be slightly lower due to some hedging of overseas costs.
- ▶ **Cashflow/net debt:** Although free cashflow (Hardman & Co definition) in 1H'18 was lower, as anticipated, than that seen in 1H'17, at £11.8m (£14.7m), it was better than forecasts, such that net debt at 30 June was -£86.3m, vs. our forecast of £89.0m, after increased working capital and paying for the acquisition of Nizoral. Leverage at 30 June was 2.4x, well below the banking covenants (3.0x).

**1H'18 results – Actual vs. expectations**

Interims to June (£m)	1H'17 actual	1H'18 actual	CER %	1H'18 forecast	Delta $\Delta$
Kelo-Cote	6.2	10.9	+93%	8.0	+2.9
MacuShield	3.0	3.7	+22%	3.8	-0.1
Vamousse	-	2.7	-	2.6	+0.1
Ametop	-	1.0	-	1.0	-
Other products	40.2	36.2	-9%	38.6	-2.4
<b>Group sales</b>	<b>49.4</b>	<b>54.5</b>	<b>+5%</b>	<b>54.0</b>	<b>+0.5</b>
Underlying EBIT	14.0			15.0	
EBIT margin (%)	28.3%			27.5%	
Free cashflow*	14.7	11.8		8.2	+3.6
<b>Net cash//(debt)</b>	<b>-63.3</b>	<b>-86.3</b>		<b>-89.0</b>	<b>+2.7</b>

Numbers may not add up exactly due to rounding

\*Hardman & Co definition, includes exceptional

Source: Hardman & Co Life Sciences Research

- ▶ **2018 forecasts:** There is nothing material in the half-year numbers/trading statement that would cause us to change full-year forecasts. However, the remainder of this report does highlight a number of changes resulting from the acquisition of Nizoral in June and the UK approval of Xonvea in July. Details of the changes are shown on page 11.

## Nizoral acquisition

### Nizoral\* APAC sales



Korea 2% Shampoo



China 2% Shampoo



Japan 2% Lotion



Korea 2% Shampoo



Philippines 1% Shampoo



India 2% Shampoo

**Johnson & Johnson**

2017 sales: \$25.0m/£18.5m

\*Nizoral shampoo/lotion  
Source: J&J/Alliance Pharma

### Deal with Johnson & Johnson (J&J)

#### Key features

- ▶ APH has acquired the exclusive rights to Nizoral in the Asia-Pacific region (APAC).
- ▶ The deal includes Nizoral shampoos (1% and 2%) and a lotion (Japan only).
- ▶ This is an established brand that will boost APH's already growing APAC sales by 2.6x.
- ▶ Existing APH presence and distributor relationships will facilitate a rapid and smooth handover.
- ▶ New countries and established distributor relationships will expand APH's presence in the APAC region.
- ▶ J&J to retain rights to Nizoral creams; J&J will not be allowed to sell ketoconazole products for hair/scalp for three years, nor Nizoral branded shampoos in perpetuity, in APAC.

### Nizoral: anti-dandruff brand

#### History

The active pharmaceutical ingredient (API) in Nizoral is the antifungal agent ketoconazole, discovered in 1976 by J&J's R&D division, Janssen Research and Development. Oral and topical products containing ketoconazole enjoyed strong sales growth following first launch in the US in 1985, with sales peaking at \$413m in 1998. Patent expiry of the active ingredient in the early 2000s and FDA withdrawal of the compound in oral medications in 2013 led to a weakening in J&J's worldwide Nizoral sales. Over the last 15-20 years, Nizoral has been repositioned and is now sold predominantly in OTC products, such as shampoos.

## Nizoral formulations




Source: J&J/Alliance Pharma

The brand has been de-prioritised by J&J globally, in line with the news in December 2017 that it was considering a disposal of Nizoral as part of a general streamlining of its portfolio. APH has acquired the rights solely for the APAC region.

### Ketoconazole

Like all '-azole' drugs, ketoconazole targets synthesis of ergosterol, a component of the fungal cell membrane. Ketoconazole is the most commonly prescribed ingredient for seborrhic capitis and seborrheic dermatitis, which cause dandruff – dandruff affects up to half the population. Having been on the market in various forms for more than 30 years, ketoconazole has a well-established clinical profile.

## Nizoral\* sales – APAC region



\*Nizoral shampoo/lotion  
Source: Alliance Pharma

### Geographical sales performance

Nizoral rights to more than 15 APAC countries have been acquired by APH from J&J. In 2017, 70% of sales in APAC were generated fairly evenly among five countries, diminishing risk in the short term and permitting potential growth by APH in additional countries in the medium- to long-term. Under J&J, marketing spend was only ca.£300k p.a. (presumably in territories covered directly by the J&J sales team – Taiwan, Philippines and India).

### Competition

There are two main competitors to Nizoral in APAC: Kang Wang shampoo is marketed by Bayer and includes a steroid in addition to ketoconazole; and Selsun Blue, marketed by Sanofi, which includes the antifungal agent selenium sulphide.

### Next steps

Both APH and J&J have appointed representatives to a small management team that will oversee the transfer and integration process.

In order to have a smooth transition, APH has entered into a five-year manufacturing services agreement with J&J, for the supply of active pharmaceutical ingredient (API) and manufacture of the final product which is manufactured by J&J. Products not manufactured by J&J will continue to be undertaken by Contract Manufacturing Organisations (CMOs) appointed by J&J and approved by local health authorities.

Nizoral will continue to be sold under the ‘Johnson & Johnson’ name until product licences have been re-registered to APH.

APH also has a two-year Transition Service Agreement (TSA) with J&J to allow time for the transfer of ca.30 Nizoral marketing authorisations to APH. Having undertaken exactly the same process with ca.100 licences as part of the Sinclair acquisition, this is expected to be relatively straightforward. The companies have, however, allowed for 12-month extensions to the TSA should the need arise.

During the TSA period, APH will also be integrating its acquisition of Vamousse, the shampoo for treatment of head lice, and we believe that it will be preparing to obtain the Vamousse licences in APAC, with the aim to sell it through distributor networks acquired through Nizoral in addition to its established channels. As medicated shampoos, the products are complementary and will likely provide a cross-selling opportunity.

## Financial assessment

On 21 June 2018, APH concluded the acquisition of exclusive Nizoral marketing rights for the APAC region from J&J for £60.0m. The cash consideration was funded, in part, by a Placing of shares which raised £34.0m gross new capital, coupled with an extension of its loan facility by £35.0m, of which £27.9m was drawn down. This balance of equity and debt enabled the company to keep its net debt/EBITDA at around the 2.5x level immediately upon closure of the transaction, with a view for positive cashflow to reduce this to a target 2.0x within 12 months.

### Deal summary

- ▶ **Nizoral performance:** Sales in 2017 were \$25.0m/£18.5m and, applying costs on a *pro forma* basis, the EBITDA was \$9.6m/£7.1m.
- ▶ **Deal metrics:** The cash consideration represents EV/sales of 3.2x and EV/EBITDA of 8.5x.
- ▶ **Placing:** £34.0m gross (£32.1m net of total acquisition costs) was raised via a Placing of 37.36m new Ordinary shares in the company @91p per share, which represented a 10.3% discount to the mid-market price on the day of the book build (19 June 2018).
- ▶ **Debt:** The remainder of the cash consideration was through a drawdown of £27.9m of the company's extended £35.0m debt facility, which gave a leverage of 2.5x at the time of the deal closure.
- ▶ **Integration:** APH has agreed a two-year TSA with J&J, which could be extended by periods of 12 months should the need arise, to allow for the transfer of ca.30 marketing authorisations.
- ▶ **Manufacturing:** APH has entered into a five-year Manufacturing Service Agreement (MSA) with J&J for the supply of drug substance, which will be finished and packaged by a local, approved contract manufacturing organisation (CMO).
- ▶ **Accounting:** APH will show two versions of its P&L. It will focus on the 'see-through' version, where Nizoral sales and costs will be shown as if APH were in full control of the product, which will give a better guide to the underlying performance. It will also provide statutory numbers under the TSA agreement with J&J, where the net profit in Euros will be recorded as sales. Under both versions, the EBITDA will be the same figure.



## Transforming APH's business

The acquisition of Nizoral, the recent purchases of Vamousse and Ametop, and the UK approval of Xonvea, are changing APH's business and growth prospects considerably.

The APAC region represented 11% of APH sales in fiscal 2017, all from the acquisition of Sinclair products in 2015. Nizoral has the effect of doubling this business area and adding some new and well-respected distribution channels, particularly in Thailand (DKSH) and Singapore and Malaysia (Zuellig Pharma). Nizoral will fit neatly into APH's existing infrastructure and we would expect APH to increase its existing presence in Singapore to manage the commercial and operational aspects of the business.

In our opinion, management has the intention of internationalising Vamousse, which is complementary to Nizoral, and may go through the existing and new commercialisation channels.

### Impact of recent acquisitions on APH sales




Both graphics have been adjusted (sales reduced by £2.0m est) for the adoption of IFRS 15, all of which has been applied to the UK  
Source: Alliance Pharma, Hardman & Co Life Sciences Research

### Sales and EBITDA progression

Given that J&J had announced its intention to focus on major global brands and to dispose of other brands it no longer considers core, it is unsurprising that the likes of Nizoral have received little marketing support and investment over recent years. This has resulted in a relatively static sales and EBITDA pattern. It does, however, highlight the strength of the brand, even in the absence of investment, and how, with some modest attention from APH, it could be brought back into growth.

### Nizoral sales and EBITDA trend in APAC



Source: J&J/Alliance Pharma

### Change of Chinese distributor

In addition, J&J decided to change its Chinese distributor in 2017, which had a temporary detrimental impact on sales and profits. The outgoing distributor was passive, and J&J decided to move to a more proactive partner, Jointown. Initially, this led to unusual buying patterns, with the outgoing distributor buying up stock and saturating the market to maximise its returns.

The consequence was that Jointment made few sales in 2017. This led to a sales decline of ca.\$3.5m/£2.7m last year and, in our opinion, much of this came straight off EBITDA. Excluding sales in China, the performance of Nizoral has been consistent, in the range of \$21m-\$23m, in APAC.


### Impact of changing distributor in China



Source: J&J/Alliance Pharma

Analysis of the China sales data from J&J for the first five months of 2018 has reassured APH management that this effect has washed through and that normal sales levels have returned. Consequently, we believe that sales will revert to ca.\$28m in 2018. However, due to a modest overlap in some costs during the initial two-year TSA period, *pro forma* EBITDA is likely to remain at ca.\$9.5m/£7.0m. During this period, the focus will be on achieving transfer of marketing authorisations to APH and integrating the Nizoral business into APH systems. Consequently, expectations for sales and EBITDA growth are minimal.

### Pro forma sales and EBITDA



# Xonvea (Diclectin) approved in UK

## Route to UK launch

### MHRA approval process



Source: Duchesnay

Following a lengthy process with UK regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), Diclectin received UK marketing authorisation on 6 July 2018. It will be marketed under the brand name Xonvea®, for the treatment of nausea and vomiting of pregnancy (NVP), as a prescription-only medicine.

APH and its partner, Duchesnay Inc (Canada), have been engaged with the MHRA regarding the licensing of Diclectin following the initial submission of the regulatory dossier in 2015. In July 2017, the decision from the MHRA was that the application was 'not approvable', based on the current submission package. Subsequent discussions with the MHRA and the Commission on Human Medicines (CHM), however, led to an updated Marketing Authorisation Application being submitted.

Given that Diclectin is widely used in North America, management retained optimism that the product would receive approval in 2018. With a positive opinion received from the MHRA and the CHM in June 2018, followed by the final approval in July, this confidence was clearly justified.

### Launch timeline - UK

APH is expected to launch Xonvea in the UK this coming autumn. Our sales model – discussed below – estimates that UK sales could reach £6.0m by 2021, and then up to £10m p.a. at peak. The initial benefit to sales in fiscal 2018 and 2019, however, will be more than offset by the short-term launch and marketing costs.

### Rights in-licensed from Duchesnay

For the UK rights agreement, APH paid a licensing fee of £1.5m to Duchesnay, with £0.5m on signing, £0.5m on regulatory submission, and the balance of £0.5m now payable due to UK approval. APH has also in-licensed the rights to Xonvea in a further nine European countries, for another £1.0m. Under both agreements, Duchesnay will manufacture Xonvea for APH and will receive royalties on net sales, which APH will account for as part of COGS.

### Submissions in nine additional European territories

Filing submissions for regulatory approval in the continental European countries are being prepared by APH, and, therefore, additional international launches can be expected in the medium term. The total potential market opportunity is ca.£30m for APH in European markets outside of the UK.

## Unmet need

### Nausea and vomiting of pregnancy (NVP)

Morning sickness is very common in pregnancy; however, the severity of the condition is extremely variable. In an extensive review of 26 publications involving 39,710 expectant mothers, the incidence of NVP was 73.4%<sup>1</sup>, and the symptoms lasted a median of 41 days. The severity of the condition determines the likelihood that a patient will seek treatment, and also the number of tablets that will be taken.

<sup>1</sup> <https://www.pregnancysicknesssupport.org.uk/resources/literature-review/incidence-of-nausea-and-vomiting-in-pregnancy-nvp/>

The four classifications of the frequency and severity of NPV are:

- ▶ Hyperemesis gravidarum – occurs in 3% of patients and requires hospitalisation
- ▶ Severe – occurs in about 11%
- ▶ Moderate – occurs in about 30%
- ▶ Mild – occurs in about 26%

*Diclectin used by >33 million women in*

*Canada since launch...*

*...and given category A safety rating by FDA*

### *Diclectin – established safety and efficacy profile*

Diclectin has been used by more than 33 million women for more than 30 years, having been sold in Canada since 1976. It is also approved in the US, where it is sold as Diclegis, having received authorisation from the FDA in 2013 and a category A safety rating. As such, Diclectin has an established efficacy and safety profile with extensive real-world data. The active ingredients (doxylamine and pyridoxine) of Diclectin have been used for many years. The formulation is film-coated (to prevent the actives being broken down by acid in the stomach), and it is a delayed release formulation, so that it can be taken at night for a maximum effect in the morning.

### *Sales model in Europe*

Applying the known market share figure derived from the US (12% in 2016)<sup>2</sup> to APH's markets in Europe indicates that Diclectin will be a £40m opportunity for the group by five years after launch, as highlight below:

- ▶ Ex-factory sales of ca.£10m in the UK, five years from the end of 2018.
- ▶ Ex-factory sales of ca.€35m/£30m from Europe on a staggered launch strategy over five years, expected to start around the end of 2019.

### Xonvea – UK market opportunity based on 2016 data

Example 2016 data

United Kingdom	
Live births	779,499
NVP patients	545,649
Price for five to six weeks (£)	168.0
Utilisation	<b>12.2%</b>
Gross sales (£m)	11.2
Opportunity: net sales (£m)	<b>9.8</b>
Top nine Europe	
Live births	2,558,540
NVP patients	1,790,978
Price for five to six weeks (€)	193.2
Utilisation rate (year three from US)	<b>12.2%</b>
Gross sales (€m)	42.3
Net sales (€m)	<b>34.5</b>
Opportunity: net sales (€m)	<b>30.0</b>

*Live birth statistics taken from Eurostat  
Source: Hardman & Co Life Sciences Research*

<sup>2</sup><http://www.hardmanandco.com/docs/default-source/company-docs/alliance-pharma-documents/25.01.17-potential-of-diclectin.pdf>

## Changes to forecasts

In principle, the changes to forecasts from the Nizoral acquisition are straightforward, with the simple addition of ca.\$28m/£22m of sales in each of the next three years and, at the EBITDA level, a normalised (allowing for Chinese distributor change) rate of \$9.5m/£7.0m being included. In practice, the changes will be more complicated:

- ▶ During the TSA period, variable by territory until product licences are transferred, APH will not report the sales and costs incurred by J&J in its statutory P&L.
- ▶ APH will report the accrued net income due from J&J through its sales line during the TSA. Moreover, this will be calculated from invoices that are drawn up in local currencies, less costs, but paid as a lump sum in EUR. Therefore, there is currency exposure from the trading quarter to the payment date (105 days).
- ▶ Integration/infrastructure costs will be incurred from 2019 as marketing authorisations start to be transferred.
- ▶ From the financing side, net interest will rise by an estimated £1.3m p.a. in respect of the extra debt, and the dividend payment will rise by £0.55m to reflect the increased number of shares in issue following the Placing.

The net effect of all of this will be a minimal benefit to EPS in the first 12 months, which rises modestly each year until the TSA has finished and full integration of all the product licences has been achieved (in 2021).

For Xonvea, the up-front launch costs for UK and Europe have been included from 2H'18 and 2H'19 respectively. Material sales are not expected to flow through until 2019 in the UK and 2021 in EU. Details are shown in the table below:

<b>Changes to forecasts (all at constant currency)</b>				
<b>Year-end Dec (£m)</b>	<b>2017</b>	<b>2018E</b>	<b>2019E</b>	<b>2020E</b>
Previous sales forecast	103.3	118.0	127.0	135.0
Adoption of IFRS 15	-2.0	-2.1	-2.2	-2.4
J&J net profit transfer	-	3.7	7.4	7.5
Xonvea sales (UK + EU)	-	0.1	1.8	4.5
<b>Statutory sales</b>	<b>101.3</b>	<b>119.7</b>	<b>134.0</b>	<b>144.0</b>
<i>Pro forma</i> product sales	127.0	137.7	148.2	158.7
Previous statutory EBITDA	31.1	32.6	33.8	36.9
Previous underlying EBITDA forecast	28.2	32.6	35.3	38.4
Nizoral EBITDA contribution	-	3.7	7.4	7.5
Integration/infrastructure costs	-	-	-0.6	-0.9
Xonvea EBITDA contribution	-	-2.6	-2.6	-3.0
Revised underlying EBITDA	28.2	33.7	39.5	42.0
Underlying EBITDA margin	27.8%	28.2%	29.5%	29.2%
Current net interest	-2.4	-2.9	-2.3	-1.6
Additional finance costs	-	-0.6	-1.3	-1.2
Increased dividend cost	-	-0.5	-0.6	-0.7
Previous underlying basic EPS (p)	4.24	4.76	5.27	5.85
Revised underlying basic EPS (p)	-	4.64	5.31	5.80

Source: Hardman & Co Life Sciences Research

## 'See-through' accounts

APH will be providing a 'see-through' P&L account during the TSA period to provide investors with a clearer view of the underlying performance of the group. Under this version, sales and costs of Nizoral will be included as if the product were being sold by APH. It will also provide a clear picture of growth when this does occur, at the end of the TSA period (estimated at the end of 2020).

All our forecasts are at constant currency, based on the actual exchange rates for 2017, again to provide investors with a better understanding of the underlying growth rates. However, to give readers a guide to sensitivity, the estimated contribution to EBITDA from the Nizoral acquisition in 2019 is £7.4m at CER, which would reduce to £7.0m if it were translated at the exchange rate used in the acquisition announcement (USD 1.35; EUR 1.13).

<b>'See-through' profit &amp; loss account</b>				
<b>Year-end Dec (£m)</b>	<b>2017</b>	<b>2018E</b>	<b>2019E</b>	<b>2020E</b>
GBP:EUR	1.141	1.141	1.141	1.141
GBP:USD	1.289	1.289	1.289	1.289
<b>Sales</b>	<b>101.3</b>	<b>126.8</b>	<b>148.2</b>	<b>158.7</b>
Cost of goods	-42.4	-52.3	-61.4	-65.2
Gross profit	59.0	74.5	86.8	93.5
Admin & marketing	-31.7	-42.2	-48.9	-52.8
<b>Underlying EBITDA</b>	<b>28.2</b>	<b>33.7</b>	<b>39.5</b>	<b>42.0</b>
EBITDA margin	27.8%	26.6%	26.7%	26.5%
Reported EBITDA	31.1	33.8	38.0	40.5
Depreciation	-0.7	-1.2	-1.5	-1.5
Amortisation	-0.3	-0.2	-0.2	-0.2
Other income	0.0	0.0	0.0	0.0
<b>Underlying EBIT</b>	<b>27.3</b>	<b>32.3</b>	<b>37.8</b>	<b>40.3</b>
Share-based costs	-1.5	-1.5	-1.5	-1.5
Exceptional items	*4.4	**1.5	0.0	0.0
Statutory EBIT	30.2	32.4	36.3	38.9
Net interest	-2.4	-3.5	-3.7	-3.0
Other financials	0.6	0.1	0.1	0.1
<b>Underlying pre-tax profit</b>	<b>24.8</b>	<b>28.8</b>	<b>34.1</b>	<b>37.3</b>
Extraordinary items	0.0	0.0	0.0	0.0
<b>Reported pre-tax</b>	<b>28.4</b>	<b>28.9</b>	<b>32.7</b>	<b>35.9</b>
Underlying tax	-4.8	-5.8	-6.8	-7.5
Tax rate	19%	20%	20%	20%
Exceptional tax	5.3	0.0	0.0	0.0
Tax payable/credit	0.5	-5.8	-6.8	-7.5
<b>Underlying net income</b>	<b>20.1</b>	<b>23.0</b>	<b>27.3</b>	<b>29.8</b>
Statutory net income	28.9	23.1	25.9	28.4
<b>Ordinary 1p shares:</b>				
Weighted average (m)	473.8	496.0	514.2	514.2
<b>Underlying basic EPS (p)</b>	<b>4.24</b>	<b>4.64</b>	<b>5.31</b>	<b>5.80</b>
Statutory basic EPS (p)	6.10	4.66	5.03	5.53

\*Includes £5.0m warranty settlement for Kelo-stretch

\*\*Profit on disposal of 60% share of Unigreg JV

Source: Hardman & Co Life Sciences Research

## Financials and investment case

### Profit & Loss

- ▶ **Sales:** The J&J profit transfer, based on the net profit from Nizoral sales in the APAC region, will be included in APH sales. Once this is known at the end of each quarter, APH will take a transaction hedge to cover the EUR amount.
- ▶ **EBITDA margin:** This will be variable over the forecast period due to investment in launching Xonvea and the accounting of Nizoral during the TSA period.

<b>Profit &amp; loss account</b>						
Year-end Dec (£m)	2015	2016	2017	2018E	2019E	2020E
GBP:EUR	1.284	1.223	1.141	1.141	1.141	1.141
GBP:USD	1.432	1.354	1.289	1.289	1.289	1.289
<b>Sales</b>	<b>48.3</b>	<b>97.5</b>	<b>101.3</b>	<b>119.7</b>	<b>134.0</b>	<b>144.0</b>
Cost of goods	-19.6	-42.6	-42.4	-47.0	-50.8	-54.3
Gross profit	28.7	54.8	59.0	72.6	83.2	89.7
Admin & marketing	-15.6	-28.8	-31.7	-40.3	-45.4	-49.4
<b>Underlying EBITDA</b>	<b>13.6</b>	<b>26.7</b>	<b>28.2</b>	<b>33.7</b>	<b>39.5</b>	<b>42.0</b>
EBITDA margin	28.1%	27.4%	27.8%	28.2%	29.5%	29.2%
Reported EBITDA	17.5	26.0	31.1	33.8	38.0	40.5
Depreciation	-0.3	-0.3	-0.7	-1.2	-1.5	-1.5
Amortisation	-0.2	-0.1	-0.3	-0.2	-0.2	-0.2
Other income	0.0	0.0	0.0	0.0	0.0	0.0
Share of JV profits/(loss)	0.2	0.3	0.0	0.0	0.0	0.0
<b>Underlying EBIT</b>	<b>13.3</b>	<b>26.3</b>	<b>27.3</b>	<b>32.3</b>	<b>37.8</b>	<b>40.3</b>
Share-based costs	-0.6	-0.7	-1.5	-1.5	-1.5	-1.5
Exceptional items	4.5	0.0	4.4	1.5	0.0	0.0
Statutory EBIT	17.0	25.6	30.2	32.4	36.3	38.9
Net interest	-1.1	-2.8	-2.4	-3.5	-3.7	-3.0
Other financials	-0.7	-0.6	0.6	0.1	0.1	0.1
<b>U/lying pre-tax profit</b>	<b>12.2</b>	<b>23.5</b>	<b>24.8</b>	<b>28.8</b>	<b>34.1</b>	<b>37.3</b>
Extraordinary items	0.0	0.0	0.0	0.0	0.0	0.0
<b>Reported PBT</b>	<b>15.2</b>	<b>22.2</b>	<b>28.4</b>	<b>28.9</b>	<b>32.7</b>	<b>35.9</b>
Underlying tax	-1.4	-4.9	-4.8	-5.8	-6.8	-7.5
Underlying tax rate	11.3%	20.7%	19.1%	20.0%	20.0%	20.0%
Exceptional tax	-1.1	0.8	5.3	0.0	0.0	0.0
Tax payable/credit	-2.5	-4.1	0.5	-5.8	-6.8	-7.5
<b>Underlying net income</b>	<b>10.8</b>	<b>18.7</b>	<b>20.1</b>	<b>23.0</b>	<b>27.3</b>	<b>29.8</b>
Statutory net income	12.7	18.1	28.9	23.1	25.9	28.4
<b>Ordinary 1p shares:</b>						
Period-end (m)	468.2	472.6	475.0	514.2	514.2	514.2
Weighted average (m)	272.7	469.4	473.8	496.0	514.2	514.2
Fully-diluted (m)	299.2	505.0	513.7	535.9	554.1	554.1
<b>U/lying basic EPS (p)</b>	<b>3.97</b>	<b>3.98</b>	<b>4.24</b>	<b>4.64</b>	<b>5.31</b>	<b>5.80</b>
Statutory basic EPS (p)	4.65	3.85	6.10	4.66	5.03	5.53
<b>U/lying fully-dil. EPS (p)</b>	<b>3.62</b>	<b>3.70</b>	<b>3.91</b>	<b>4.30</b>	<b>4.92</b>	<b>5.38</b>
Stat. fully-dil. EPS (p)	4.24	3.58	5.63	4.32	4.67	5.13
<b>DPS (p)</b>	<b>1.10</b>	<b>1.21</b>	<b>1.33</b>	<b>1.46</b>	<b>1.61</b>	<b>1.77</b>

\*Includes £5.0m warranty settlement for Kelo-stretch

\*\*Profit on disposal of 60% share of Unigreg JV

Source: Hardman & Co Life Sciences Research

## Balance sheet

- ▶ **Intangible assets:** Nizoral will be included at cost on the balance sheet as part of the intangibles, and will not be amortised.
- ▶ **Leverage:** At the point of closing the deal with J&J, management indicated that leverage would be 2.5x. We expect net/debt/EBITDA to fall in subsequent fiscal years.

<b>Balance sheet</b>						
<b>@31st December (£m)</b>	<b>2015</b>	<b>2016</b>	<b>2017</b>	<b>2018E</b>	<b>2019E</b>	<b>2020E</b>
Shareholders' funds	162.4	179.3	203.4	253.0	270.6	289.9
Cumulated goodwill	26.0	26.0	26.0	26.0	26.0	26.0
Total equity	188.5	205.3	229.4	279.0	296.6	316.0
Share capital	4.7	4.7	4.8	5.1	5.1	5.1
Reserves	157.8	174.5	198.6	247.8	265.4	284.8
Provisions/liabilities	1.5	1.7	3.4	3.4	3.4	3.4
Deferred tax	37.0	29.7	24.7	24.7	24.7	24.7
Long-term loans	59.0	57.6	41.8	57.2	49.3	40.7
Short-term debt	15.8	25.8	41.7	41.7	33.8	25.2
less: Cash	3.2	7.2	11.2	11.2	11.2	11.2
<b>Invested capital</b>	<b>272.5</b>	<b>286.8</b>	<b>303.9</b>	<b>368.9</b>	<b>370.7</b>	<b>372.9</b>
Fixed assets	1.0	1.8	3.4	3.7	3.3	3.0
Intangible assets	233.9	238.5	252.6	312.6	312.6	312.6
JV assets	2.9	2.9	2.9	0.0	0.0	0.0
Goodwill	26.0	26.0	26.0	26.0	26.0	26.0
Inventories	12.9	15.4	14.2	16.8	18.8	20.3
Trade debtors	8.8	20.5	17.3	25.1	28.2	30.3
Other debtors	2.8	6.2	6.3	7.5	8.4	9.0
Tax liability/credit	-2.1	-2.5	-2.4	-2.6	-2.7	-2.8
Trade creditors	-1.2	-5.7	-6.7	-7.4	-8.0	-8.5
Other creditors	-12.7	-16.3	-9.9	-13.0	-15.9	-16.9
Debtors less creditors	-4.3	2.2	4.7	9.7	10.0	11.0
<b>Invested capital</b>	<b>272.5</b>	<b>286.8</b>	<b>303.9</b>	<b>368.9</b>	<b>370.7</b>	<b>372.9</b>

Source: Hardman & Co Life Sciences Research

<b>Key metrics</b>						
<b>Year-end Dec (£m)</b>	<b>2015</b>	<b>2016</b>	<b>2017</b>	<b>2018E</b>	<b>2019E</b>	<b>2020E</b>
Net cash/(debt)	-71.5	-76.1	-72.3	-87.7	-71.9	-54.7
Net debt/EBITDA (x)	5.3	2.8	2.6	2.5	1.8	1.3
Net debt/equity (%)	-38%	-37%	-32%	-31%	-24%	-17%
NAV/share (p)	35	38	43	49	53	56
Stock days	71	53	53	47	49	50
Debtor days	58	77	68	65	73	74
Creditor days	57	48	57	57	57	57
Interest cover (x)	11.0	9.2	9.1	9.0	10.2	13.3
Dividend cover (x)	3.6	3.3	3.2	3.2	3.3	3.3
Cap-ex/depreciation (x)	2.7	3.4	3.4	1.3	0.7	0.8
NOPAT	11.8	20.9	17.6	25.8	30.2	32.2
After-tax ROIC	4.3%	7.3%	5.8%	7.0%	8.2%	8.6%
Cap-ex/sales	1.3%	1.2%	2.2%	1.3%	0.7%	0.8%

---

 Source: Hardman & Co Life Sciences Research

## Cashflow

- ▶ **Consideration:** The cash consideration of £60.0m was part-funded by the Placing of shares, which raised gross new funds of £32.1m; the remainder being paid with new debt.
- ▶ **Amortisation:** There will be no change to the amortisation charge, as the full cost will be held on the balance sheet and, consistent with other consumer products, is expected to maintain value, provided it receives appropriate marketing support.
- ▶ **Dividend costs:** The increase in the number of shares in issue to pay for Nizoral will increase accrued dividend costs by £0.55m in 2018, which will be paid during calendar 2019.



Cashflow						
Year-end Dec (£m)	2015	2016	2017	2018E	2019E	2020E
Underlying EBIT	13.3	26.3	27.3	32.3	37.8	40.3
Depreciation	0.2	0.3	0.7	1.2	1.5	1.5
Amortisation	0.2	0.1	0.3	0.2	0.2	0.2
<i>Inventories</i>	-7.0	-2.4	1.1	-2.6	-2.0	-1.4
<i>Receivables</i>	2.3	-14.1	4.0	-7.8	-3.0	-2.1
<i>Payables</i>	-3.3	10.1	-3.0	0.7	0.6	0.6
Change in working capital	-8.0	-6.5	2.1	-9.6	-4.4	-3.0
Exceptionals/provisions	4.5	0.0	4.0	1.0	0.0	0.0
Other	-0.1	-0.3	0.5	0.0	0.0	0.0
<b>Cashflow from ops.</b>	<b>10.1</b>	<b>20.0</b>	<b>34.9</b>	<b>25.1</b>	<b>35.1</b>	<b>39.0</b>
Net interest	-1.0	-3.0	-2.6	-3.5	-3.7	-3.0
Tax paid/received	-1.9	-3.0	-3.7	-4.3	-5.6	-7.1
<b>Operational cashflow</b>	<b>7.2</b>	<b>13.9</b>	<b>28.6</b>	<b>17.3</b>	<b>25.7</b>	<b>28.9</b>
Capital expenditure	-0.6	-1.1	-2.2	-1.5	-1.0	-1.2
Capitalised R&D	0.0	-0.3	-0.5	-0.5	-0.5	-0.5
Sale of fixed assets	0.0	0.0	0.0	0.0	0.0	0.0
<b>Free cashflow</b>	<b>6.6</b>	<b>12.5</b>	<b>25.9</b>	<b>15.3</b>	<b>24.3</b>	<b>27.3</b>
Acquisitions	133.9	-6.0	-17.5	-60.0	-1.5	-1.9
Disposals	0.0	0.0	0.0	2.4	0.5	0.0
Dividends	-2.6	-5.2	-5.4	-6.7	-7.5	-8.3
Other investments	0.0	-1.0	0.2	0.0	0.0	0.0
<b>CF after investments</b>	<b>129.9</b>	<b>0.3</b>	<b>3.1</b>	<b>-49.0</b>	<b>15.7</b>	<b>17.2</b>
Share repurchases	0.0	0.0	0.0	0.0	0.0	0.0
Capital increases	79.8	1.3	0.7	32.1	0.0	0.0
Currency effect	-0.1	-6.2	0.0	0.0	0.0	0.0
<b>Change in net debt</b>	<b>50.2</b>	<b>-4.6</b>	<b>3.8</b>	<b>-15.4</b>	<b>15.7</b>	<b>17.2</b>
Opening net cash/(debt)	21.1	-71.4	-75.9	-72.1	-87.5	-71.7
<b>Closing net cash/(debt)</b>	<b>71.4</b>	<b>-75.9</b>	<b>-72.1</b>	<b>-87.5</b>	<b>-71.7</b>	<b>-54.5</b>
Hardman CF/share (p)	2.4	2.7	5.5	3.1	4.7	5.3

Definition of free cashflow includes exceptional items  
Source: Hardman & Co Life Sciences Research

## Valuation

APH is trading on a 2018E PE of 20.1x, falling to 17.6x in 2019E with a full 12-month contribution from the Nizoral acquisition, with an underlying CAGR EPS 2017-20E of ca.11%. However, this includes the establishment of its US operation, the launch investment in Xonvea in both the UK and EU, and the 'depleted' profit contribution from Nizoral during the TSA period. The prospective dividend yield is 1.6% with a progressive dividend policy that is currently covered 3.2x.

APH is generating ROIC of 8%-9%, with some of the free cashflow being reinvested into product acquisitions, as evidenced recently with Ametop and Vamousse. We forecast underlying free cashflow to be in the range of £25.0m-£30.0m when full contributions from Nizoral are included, which will be used primarily to pay down borrowings, or to fund small, bolt-on acquisitions.



# Company matters

## Registration

Incorporated in England and Wales with company registration number: 04241478

### UK Headquarters:

Avonbridge House  
Bath Road  
Chippenham  
Wiltshire  
SN15 2BB

+44 1249 466 966

[www.alliancepharmaceuticals.com](http://www.alliancepharmaceuticals.com)

## Board of Directors

<b>Board of Directors</b>					
Position	Name	Nominations	Remuneration	Audit	
Chairman	David Cook	M	M	C	
Chief Executive Officer	Peter Butterfield				
Chief Financial Officer	Andrew Franklin				
Non-executive director	Nigel Clifford	C	C	M	
Non-executive director	John Dawson	M			


*M = member; C = chair*

*Source: Company reports*

## Share capital

Number of Ordinary shares in issue on 24 July 2018: 514,205,522.

Number of options outstanding: 39.90 million.



## Notes

## Disclaimer

Hardman & Co provides professional independent research services and all information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable. However, no guarantee, warranty or representation, express or implied, can be given by Hardman & Co as to the accuracy, adequacy or completeness of the information contained in this research and they are not responsible for any errors or omissions or results obtained from use of such information. Neither Hardman & Co, nor any affiliates, officers, directors or employees accept any liability or responsibility in respect of the information which is subject to change without notice and may only be correct at the stated date of their issue, except in the case of gross negligence, fraud or wilful misconduct. In no event will Hardman & Co, its affiliates or any such parties be liable to you for any direct, special, indirect, consequential, incidental damages or any other damages of any kind even if Hardman & Co has been advised of the possibility thereof.

This research has been prepared purely for information purposes, and nothing in this report should be construed as an offer, or the solicitation of an offer, to buy or sell any security, product, service or investment. The research reflects the objective views of the analyst(s) named on the front page and does not constitute investment advice. However, the companies or legal entities covered in this research may pay us a fixed fee in order for this research to be made available. A full list of companies or legal entities that have paid us for coverage within the past 12 months can be viewed at <http://www.hardmanandco.com/legal/research-disclosures>. Hardman may provide other investment banking services to the companies or legal entities mentioned in this report.

Hardman & Co has a personal dealing policy which restricts staff and consultants' dealing in shares, bonds or other related instruments of companies or legal entities which pay Hardman & Co for any services, including research. No Hardman & Co staff, consultants or officers are employed or engaged by the companies or legal entities covered by this document in any capacity other than through Hardman & Co.

Hardman & Co does not buy or sell shares, either for their own account or for other parties and neither do they undertake investment business. We may provide investment banking services to corporate clients. Hardman & Co does not make recommendations. Accordingly, they do not publish records of their past recommendations. Where a Fair Value price is given in a research note, such as a DCF or peer comparison, this is the theoretical result of a study of a range of possible outcomes, and not a forecast of a likely share price. Hardman & Co may publish further notes on these securities, companies and legal entities but has no scheduled commitment and may cease to follow these securities, companies and legal entities without notice.

The information provided in this document is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject Hardman & Co or its affiliates to any registration requirement within such jurisdiction or country.

Some or all alternative investments may not be suitable for certain investors. Investments in small and mid-cap corporations and foreign entities are speculative and involve a high degree of risk. An investor could lose all or a substantial amount of his or her investment. Investments may be leveraged and performance may be volatile; they may have high fees and expenses that reduce returns. Securities or legal entities mentioned in this document may not be suitable or appropriate for all investors. Where this document refers to a particular tax treatment, the tax treatment will depend on each investor's particular circumstances and may be subject to future change. Each investor's particular needs, investment objectives and financial situation were not taken into account in the preparation of this document and the material contained herein. Each investor must make his or her own independent decisions and obtain their own independent advice regarding any information, projects, securities, tax treatment or financial instruments mentioned herein. The fact that Hardman & Co has made available through this document various information constitutes neither a recommendation to enter into a particular transaction nor a representation that any financial instrument is suitable or appropriate for you. Each investor should consider whether an investment strategy of the purchase or sale of any product or security is appropriate for them in the light of their investment needs, objectives and financial circumstances.

This document constitutes a 'financial promotion' for the purposes of section 21 Financial Services and Markets Act 2000 (United Kingdom) ('FSMA') and accordingly has been approved by Capital Markets Strategy Ltd which is authorised and regulated by the Financial Conduct Authority (FCA).

No part of this document may be reproduced, stored in a retrieval system or transmitted in any form or by any means, mechanical, photocopying, recording or otherwise, without prior permission from Hardman & Co. By accepting this document, the recipient agrees to be bound by the limitations set out in this notice. This notice shall be governed and construed in accordance with English law. Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the FCA under registration number 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

(Disclaimer Version 8 – Effective from August 2018)

## Status of Hardman & Co's research under MiFID II

Some professional investors, who are subject to the new MiFID II rules from 3rd January, may be unclear about the status of Hardman & Co research and, specifically, whether it can be accepted without a commercial arrangement. Hardman & Co's research is paid for by the companies, legal entities and issuers about which we write and, as such, falls within the scope of 'minor non-monetary benefits', as defined in the Markets in Financial Instruments Directive II.

In particular, Article 12(3) of the Directive states: 'The following benefits shall qualify as acceptable minor non-monetary benefits only if they are: (b) 'written material from a third party that is commissioned and paid for by a corporate issuer or potential issuer to promote a new issuance by the company, or where the third party firm is contractually engaged and paid by the issuer to produce such material on an ongoing basis, provided that the relationship is clearly disclosed in the material and that the material is made available at the same time to any investment firms wishing to receive it or to the general public...'

The fact that Hardman & Co is commissioned to write the research is disclosed in the disclaimer, and the research is widely available.

The full detail is on page 26 of the full directive, which can be accessed here: <http://ec.europa.eu/finance/docs/level-2-measures/mifid-delegated-regulation-2016-2031.pdf>

In addition, it should be noted that MiFID II's main aim is to ensure transparency in the relationship between fund managers and brokers/suppliers, and eliminate what is termed 'inducement', whereby free research is provided to fund managers to encourage them to deal with the broker. Hardman & Co is not inducing the reader of our research to trade through us, since we do not deal in any security or legal entity.

